Sanofi (NASDAQ:SNY - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of Sanofi in a report issued on Friday, April 25th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $0.99 for the quarter, up from their prior estimate of $0.93. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's Q3 2025 earnings at $1.76 EPS, FY2025 earnings at $4.56 EPS, FY2026 earnings at $5.07 EPS, FY2027 earnings at $5.21 EPS, FY2028 earnings at $5.64 EPS and FY2029 earnings at $6.19 EPS.
Several other research analysts have also recently commented on the company. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Sanofi currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.33.
Check Out Our Latest Stock Report on SNY
Sanofi Stock Up 2.3 %
Shares of SNY traded up $1.23 during mid-day trading on Monday, hitting $54.95. 1,687,068 shares of the company's stock were exchanged, compared to its average volume of 2,837,487. The stock's 50-day moving average is $54.51 and its 200-day moving average is $52.05. The company has a market cap of $138.82 billion, a price-to-earnings ratio of 22.07, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The company's revenue was down 11.0% on a year-over-year basis.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Arkadios Wealth Advisors lifted its holdings in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock valued at $227,000 after buying an additional 751 shares during the period. Geode Capital Management LLC grew its stake in shares of Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Kentucky Trust Co acquired a new stake in shares of Sanofi in the fourth quarter valued at about $436,000. Finally, World Investment Advisors LLC boosted its holdings in Sanofi by 1,020.5% during the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock worth $2,791,000 after buying an additional 44,108 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Increases Dividend
The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's dividend payout ratio (DPR) is presently 57.14%.
About Sanofi
(
Get Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
